strensiq asfotase alfa rch 40 mg/1.00 ml solution for injection vial
alexion pharmaceuticals australasia pty ltd - asfotase alfa, quantity: 40 mg/ml - injection, solution - excipient ingredients: sodium chloride; dibasic sodium phosphate heptahydrate; water for injections; monobasic sodium phosphate monohydrate - strensiq (asfotase alfa, rch) is indicated as enzyme replacement therapy in patients with paediatric-onset hypophosphatasia.
strensiq asfotase alfa rch 80 mg/0.80 ml injection solution vial
alexion pharmaceuticals australasia pty ltd - asfotase alfa, quantity: 100 mg/ml - injection, solution - excipient ingredients: dibasic sodium phosphate heptahydrate; sodium chloride; monobasic sodium phosphate monohydrate; water for injections - strensiq (asfotase alfa, rch) is indicated as enzyme replacement therapy in patients with paediatric-onset hypophosphatasia.
alunbrig brigatinib 90 mg film-coated tablet blister pack
takeda pharmaceuticals australia pty ltd - brigatinib, quantity: 90 mg - tablet, film coated - excipient ingredients: lactose monohydrate; microcrystalline cellulose; sodium starch glycollate type a; magnesium stearate; hydrophobic colloidal silica anhydrous; titanium dioxide; purified talc; polyvinyl alcohol; macrogol 3350 - alunbrig is indicated for the treatment of adult patients with anaplastic lymphoma kinase (alk)-positive locally advanced or metastatic non-small cell lung cancer (nsclc).
alunbrig brigatinib 90 mg and 180 mg film-coated tablets blister pack
takeda pharmaceuticals australia pty ltd - brigatinib, quantity: 180 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; hydrophobic colloidal silica anhydrous; sodium starch glycollate type a; lactose monohydrate; magnesium stearate; titanium dioxide; purified talc; polyvinyl alcohol; macrogol 3350 - alunbrig is indicated for the treatment of adult patients with anaplastic lymphoma kinase (alk)-positive locally advanced or metastatic non-small cell lung cancer (nsclc).
alunbrig brigatinib 30 mg film-coated tablet blister pack
takeda pharmaceuticals australia pty ltd - brigatinib, quantity: 30 mg - tablet, film coated - excipient ingredients: lactose monohydrate; sodium starch glycollate type a; hydrophobic colloidal silica anhydrous; microcrystalline cellulose; magnesium stearate; titanium dioxide; purified talc; polyvinyl alcohol; macrogol 3350 - alunbrig is indicated for the treatment of adult patients with anaplastic lymphoma kinase (alk)-positive locally advanced or metastatic non-small cell lung cancer (nsclc).
alunbrig brigatinib 180 mg film-coated tablet blister pack
takeda pharmaceuticals australia pty ltd - brigatinib, quantity: 180 mg - tablet, film coated - excipient ingredients: hydrophobic colloidal silica anhydrous; sodium starch glycollate type a; magnesium stearate; microcrystalline cellulose; lactose monohydrate; titanium dioxide; purified talc; polyvinyl alcohol; macrogol 3350 - alunbrig is indicated for the treatment of adult patients with anaplastic lymphoma kinase (alk)-positive locally advanced or metastatic non-small cell lung cancer (nsclc).
kiovig normal immunoglobulin (human) 30g/300ml solution for injection vial
takeda pharmaceuticals australia pty ltd - normal immunoglobulin, quantity: 30 g - injection, solution - excipient ingredients: glycine; water for injections - kiovig administered intravenously is indicated for:,1. replacement therapy indications,? primary immunodeficiency disorders (pid);,? symptomatic hypogammaglobulinaemia secondary to underlying disease or treatment.,2. immunomodulation indications,? idiopathic thrombocytopenia purpura (itp), in patients at high risk of bleeding or prior to surgery to correct the platelet count;,? guillain barr? syndrome;,? kawasaki disease;,? chronic inflammatory demyelinating polyradiculoneuropathy (cidp) in adults.,? multifocal motor neuropathy (mmn).,kiovig administered subcutaneously is indicated for:,1. replacement therapy indications,? primary immunodeficiency disorders (pid).
kiovig normal immunoglobulin (human) 20g/200ml solution for injection vial
takeda pharmaceuticals australia pty ltd - normal immunoglobulin, quantity: 100 mg/ml - injection, solution - excipient ingredients: glycine; water for injections; normal immunoglobulin - kiovig administered intravenously is indicated for:,1. replacement therapy indications,? primary immunodeficiency disorders (pid);,? symptomatic hypogammaglobulinaemia secondary to underlying disease or treatment.,2. immunomodulation indications,? idiopathic thrombocytopenia purpura (itp), in patients at high risk of bleeding or prior to surgery to correct the platelet count;,? guillain barr? syndrome;,? kawasaki disease;,? chronic inflammatory demyelinating polyradiculoneuropathy (cidp) in adults.,? multifocal motor neuropathy (mmn).,kiovig administered subcutaneously is indicated for:,1. replacement therapy indications,? primary immunodeficiency disorders (pid).
kiovig normal immunoglobulin (human) 10g/100ml solution for injection vial
takeda pharmaceuticals australia pty ltd - normal immunoglobulin, quantity: 100 mg/ml - injection, solution - excipient ingredients: glycine; water for injections; human immunoglobulin a - kiovig administered intravenously is indicated for:,1. replacement therapy indications,? primary immunodeficiency disorders (pid);,? symptomatic hypogammaglobulinaemia secondary to underlying disease or treatment.,2. immunomodulation indications,? idiopathic thrombocytopenia purpura (itp), in patients at high risk of bleeding or prior to surgery to correct the platelet count;,? guillain barr? syndrome;,? kawasaki disease;,? chronic inflammatory demyelinating polyradiculoneuropathy (cidp) in adults.,? multifocal motor neuropathy (mmn).,kiovig administered subcutaneously is indicated for:,1. replacement therapy indications,? primary immunodeficiency disorders (pid).
kiovig normal immunoglobulin (human) 5g/50ml solution for injection vial
takeda pharmaceuticals australia pty ltd - normal immunoglobulin, quantity: 100 mg/ml - injection, solution - excipient ingredients: water for injections; glycine; human immunoglobulin a - kiovig administered intravenously is indicated for:,1. replacement therapy indications,? primary immunodeficiency disorders (pid);,? symptomatic hypogammaglobulinaemia secondary to underlying disease or treatment.,2. immunomodulation indications,? idiopathic thrombocytopenia purpura (itp), in patients at high risk of bleeding or prior to surgery to correct the platelet count;,? guillain barr? syndrome;,? kawasaki disease;,? chronic inflammatory demyelinating polyradiculoneuropathy (cidp) in adults.,? multifocal motor neuropathy (mmn).,kiovig administered subcutaneously is indicated for:,1. replacement therapy indications,? primary immunodeficiency disorders (pid).